GlassScriptPhysician profile
Borina Dramov
NPI 1053481515
$13,101.86
in general payments reported to CMS, 2019-2025
45 companies · $306 in 2025
The $306 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,887 · 2020: $2,248 · 2021: $2,402 · 2022: $2,083 · 2023: $1,875 · 2024: $2,301 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,481.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,829.62 | 2021-2025 | Qulipta, Ubrelvy, Duopa |
| Ucb, INC. | $1,343.21 | 2019-2025 | Briviact |
| Sk Life Science, INC. | $1,000.42 | 2020-2025 | |
| Eisai INC. | $984.68 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $884.09 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $872.77 | 2023-2025 | Fycompa |
| Teva Pharmaceuticals USA, INC. | $650.52 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Livanova USA, INC. | $509.21 | 2019-2022 | |
| Pfizer INC. | $476.27 | 2023-2025 | |
| Celgene Corporation | $420.09 | 2021-2024 | Zeposia |
| Supernus Pharmaceuticals, INC. | $418.80 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $355.02 | 2019-2021 | |
| Mdd US Operations, LLC | $306.38 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $280.58 | 2022 | |
| Kyowa Kirin, INC. | $263.85 | 2020-2024 | Nourianz |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Borina Dramov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.